Fosphenytoin Sodium Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Fosphenytoin Sodium Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
31
Registered trials
7
Result records
1
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Fosphenytoin Sodium can convert its Small molecule drug profile and SCNA biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Fosphenytoin Sodium (query alias: fosphenytoin) |
|---|---|
| Modality / target | Small molecule drug; SCNA; SCNA blockers |
| Highest global status | Approved |
| Originator | Pfizer Inc. |
| Active developers | Parke Davis Pharmaceutical Research Div Warner Lambert Co, Nobelpharma Co., Ltd., Xi'an Xintong Pharmaceutical Research Co., Ltd. |
The MCP disease footprint includes Epilepsy, Tonic-Clonic, Epilepsy, Seizures. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| JPRN-jRCT2011250056 | Phase 3 | 募集中 | 34 | Change from baseline in the mean NRS score at 60, 90, and 120 minutes after initiation of the first administration of the investigational product. |
| CTR20253943 | Not Applicable | 已完成 | 31 | Not disclosed |
| CTR20253692 | Not Applicable | 已完成 | 28 | Not disclosed |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Intravenous fosphenytoin as treatment for acute exacerbation of trigeminal neuralgia: A prospective systematic study of 15 patients.
Not Applicable; n=15; evaluation: Positive. Reported fields: Proportion of responders = 60 %
Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial.
Phase 3; n=462; evaluation: Positive. Reported fields: Efficacy = 46 % (95%CI, 34 - 59); Efficacy = 52 % (95%CI, 41 - 63); Efficacy = 44 % (95%CI, 33 - 55)
A Multicenter, Randomized, Blinded, Comparative Effectiveness Study of Fosphenytoin, Valproic Acid, or Levetiracetam in the Emergency Department Treatment of Patients With Benzodiazepine-refractory Status Epilepticus.
Phase 3; n=478; evaluation: not stated. Reported fields: Number of Participants With Clinical Cessation of Status Epilepticus - Intention to Treat = 56 Participants ; -; Number of Participants With Clinical Cessation of Status Epilepticus - Intention to Treat = 53 Participants
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Fosphenytoin Sodium addresses Epilepsy, Tonic-Clonic, Epilepsy, Seizures. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2019-11-07 | 新通药物与广东奇方关于CE-磷苯妥英钠注射液项目签署合作协议，由广东奇方该产品的的市场调研、可行性论证、销售策划 | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Preparation method of fosphenytoin sodium”. The milestone feed surfaced a patent-application signal described as “Preparation method of fosphenytoin sodium intermediate”. The milestone feed surfaced a patent-application signal described as “Fosphenytoin sodium solid composition, lyophilization method, and use of fosphenytoin sodium solid composition”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
